Showing posts with label h1n1pdm09. Show all posts
Showing posts with label h1n1pdm09. Show all posts

Friday, November 20, 2026

#USA, Weekly #US #Influenza #Surveillance Report: Key Updates for Week 45, ending November 14, 2026 (CDC, summary)

 


{Summary}

(...)

Key Points

    ° Multiple seasonal influenza surveillance indicators continue to increase nationally.

    ° Many surveillance indicators are higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater severity overall.

    ° During Week 45 (the week ending November 14, 2026), of the 613 influenza viruses reported by public health laboratories, 608 were influenza A and 5 were influenza B. Of the 365 influenza A viruses subtyped, 352 (96.4%) were influenza A(H1N1)pdm09, 12 (3.3%) were A(H3N2), and 1 (0.3%) was A(H5).

    ° Since Week 21 (the week ending May 30, 2026), 84.8% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been HA subclade E (newly designated alias of D.3.1.1).

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have circulated globally since. Influenza viruses are constantly changing, often requiring updates to influenza vaccines every season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. This week, recently  circulating influenza A(H1N1)pdm09 viruses which were previously designated D.3.1.1 HA subclade  have been reclassified into subclade E (with newly designated HA subclades E.1 to E.4), each with different combinations of genetic changes in their HA genes.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season. So far, almost all the influenza viruses collected and antigenically characterized in the U.S. since Week 21 are antigenically similar to their respective influenza vaccine reference viruses based on CDC laboratory assays.

    ° Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of seven deaths this season.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and all age groups. The severity assessment for the season changes with flu activity.

    ° CDC estimates that there have been at least 3,700,000 illnesses, 50,000 hospitalizations, and 2,800 deaths associated with flu so far this season.

    ° CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 9,200 to 36,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.7% to 7.6%.

    ° Annual seasonal flu vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now. Influenza vaccination coverage estimates and influenza vaccine doses distributed for this season are available in FluVaxView.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1

    ° One confirmed human case of avian influenza A(H5) virus infection was reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-45.html

____

Tuesday, November 17, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics Weekly Report (CDC, Nov. 17 '26): #H1N1pdm09 flu virus predominated

 


{Extract}

(...)

    The CDC explained that in week 45 (November 8-14), there were 89,487 outpatient and emergency room visits for influenza-like illnesses, a 4.3% decrease from the previous week. 

    However, last week (November 10-16), there were still 71 new cases of severe influenza complications and 37 deaths. 

    This season (October 1, 2026 - September 30, 2027) has seen a cumulative total of 716 severe cases and 157 deaths. 

    The majority of severe cases are among those aged 65 and above (69.8%) and those with a history of chronic illness (85.1%). 96.4% of those affected have not received the flu vaccine this season. 

    Laboratory monitoring data shows that the H1N1 influenza virus currently circulating in the community accounts for 94.7%. 

    According to the Taiwan Centers for Disease Control (CDC) monitoring data, the domestic COVID-19 epidemic continues to decline. 

    In week 45 (November 8-14), there were 1,432 outpatient and emergency room visits related to COVID-19, a decrease of 18.2% compared to the previous week (November 1-7). 

    Last week (November 10-16), there were still 3 new severe cases and 2 new deaths. 

    This season (October 1, 2026 - September 30, 2027) saw a cumulative total of 80 severe local cases, including 15 deaths. 

    The majority of severe cases were among those aged 65 and above (61.3%) and those with a history of chronic illnesses (85.0%). 97.5% of these cases were not vaccinated against COVID-19 this season.

(...)


Source: Taiwan's Centers for Disease Control and Prevention, https://www.cdc.gov.tw/Bulletin/Detail/W1_ZcIn7ICL7U8Z2C4mDcg?typeid=9

____

Sunday, November 15, 2026

#Zoonotic #infections and genomic #evolution of novel #reassortant swine #influenza A viruses in #Spain

 


Abstract

Influenza A virus (IAV) circulates widely in European pig populations and continues to diversify through frequent introductions from humans, followed by reassortment within swine. Spain represents a particularly dynamic ecological setting due to the coexistence of intensive white-pig production, extensive Iberian-pig systems, and abundant wild boar populations. This study provides an integrated analysis of IAV evolution and genomic diversity in swine in Spain between 2019 and 2022, expanding on previous surveillance from 2016 to 2019. Sampling across 24 provinces yielded 66 new whole-genome sequences from Iberian and white pigs. We identified 18 genotypes, including 11 novel reassortants not detected in our previous survey. Several genotypes, such as H1N2 G21 and G22, H3N2 G23, and the unusual H3N1 G12, were exclusive to the country. Some genotypes were detected across white pigs, Iberian pigs, and wild boar in Toledo and Badajoz, suggesting viral flow among swine populations. Phylogenetic analyses revealed ongoing introductions of H1N1pdm09 from humans into pigs, generating at least five reassortant genotypes (G10, G16–G19). These lineages incorporated pandemic internal cassettes and, in some cases, human-seasonal N2 segments, highlighting the continued role of humans as a source of viral incursions. Conversely, four zoonotic infections (H1N1v) detected in Spain between 2022 and 2026 were linked to genotypes circulating in white pigs, underscoring the bidirectional nature of IAV transmission at the human swine interface. Overall, this study demonstrates that Spain provides ecological conditions conducive to IAV diversification, reassortment, and zoonotic risk. The findings reinforce the need for sustained One Health surveillance.


Source: Virus Evolution Journal, https://doi.org/10.1093/ve/veag067

____

Friday, November 13, 2026

Weekly #US #Influenza #Surveillance #Report: Key Updates for Week 44, ending November 7, 2026 (CDC, summary): #H1N1pdm09 is predominant strain so far

 


{Extract}

(...)

Key Points

    ° Multiple seasonal influenza surveillance indicators continue to increase in many parts of the country.

    ° This early-season influenza activity is currently higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater overall severity.

    ° During Week 44 (the week ending November 7, 2026), of the 680 influenza viruses reported by public health laboratories, 670 were influenza A and 10 were influenza B. 

        § Of the 460 influenza A viruses subtyped, 455 (98.9%) were influenza A(H1N1)pdm09 and 5 (1.1%) were A(H3N2).

    ° Since Week 21 (the week ending May 30, 2026), 83.4% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been D.3.1.1 HA subclade.

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have caused seasonal epidemics globally since then. Influenza viruses are constantly changing, often requiring updates to influenza vaccine viruses each season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. Recently circulating influenza A(H1N1)pdm09 viruses (which are in an HA subclade called "D.3.1.1") have divided into distinct groups with different genetic changes in their HA genes. We are seeing more genetic diversity among co-circulating A(H1N1)pdm09 viruses than we have before.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season.

    ° Two pediatric deaths associated with season influenza virus infection occurring during the 2026-2027 influenza season were reported to CDC this week for a total of five deaths this season.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and for children (0-17 years), adults (18-64 years) and older adults (65+ years). The severity assessment for the season may change as flu activity is currently increasing.

    ° CDC estimates that there have been at least 2,600,000 illnesses, 36,000 hospitalizations, and 2,100 deaths associated with flu so far this season.

    ° CDC's FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 28. The number of new flu hospital admissions is forecast to range from 8,300 to 34,400 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.8% to 7.7%.

    ° Annual seasonal influenza (flu) vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-44.html

____

Tuesday, November 10, 2026

Cross #Protection against #Influenza #H5 Clade 2.3.4.4b Viruses after #H1N1pdm09 Infection

 


Abstract

We challenged ferrets previously infected with influenza A(H1N1)pdm09 virus with H5N1 or H5N5 clade 2.3.4.4b viruses to assess cross-protection. Results show that previous A(H1N1)pdm09 virus immunity conferred partial protection against both viruses, with slightly reduced protection against H5N5 compared with H5N1, potentially reflecting the absence of cross-reactive N5 neuraminidase antibodies.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.261032

____

Rare recovery of #reassortants between contemporary clade 2.3.4.4b #H5N1 viruses and #human #influenza A viruses in vitro

 


Abstract

Influenza A virus (IAV) pandemics can arise when animal-derived and human-adapted IAVs exchange genome segments; however, whether contemporary clade 2.3.4.4b H5N1 viruses can generate viable reassortants with human IAVs is unclear. Here, we tested the reassortment potential of two clade 2.3.4.4b H5N1 viruses with human-adapted H1N1 and H3N2 IAVs using a biosafe reassortment system. Across multiple coinfection conditions, we genotyped 2,698 plaque-purified viral clones and recovered 20 reassortants (0.74%). Polymerase assays identified human IAV subunits, particularly H1N1 PA or H3N2 PB2, that increased H5N1 polymerase activity. Thus, contemporary clade 2.3.4.4b H5N1 viruses can reassort with human IAVs, but factors beyond polymerase compatibility may limit their recovery.


Source: Proceedings of the National Academy of Sciences of the United States of America, https://doi.org/10.1073/pnas.2631654123

____

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics, Weekly Situation Update (CDC, Nov. 10 '26): #H1N1pdm09 flu virus still predominated

 


{Extract}

(...)

    The CDC explained that in week 44 (November 1-7), there were 91,879 outpatient and emergency room visits for influenza-like illnesses, a 6.4% decrease from the previous week. 

    However, last week (November 3-9), there were still 103 new cases of severe influenza complications and 38 deaths. 

    This season (October 1, 2026 - September 30, 2027) has seen a cumulative total of 645 severe cases and 124 deaths. 

    The majority of severe cases are among those aged 65 and above (69.6%) and those with a history of chronic illness (85.1%). 

    97.1% of those affected have not received the seasonal influenza vaccine. 

    Laboratory monitoring data shows that H1N1 influenza viruses are currently predominantly circulating in the community, accounting for 94.7%. 

    

    According to the Taiwan Centers for Disease Control (CDC), although the COVID-19 epidemic in Taiwan ended its peak in mid-October and continues to decline, last week (November 3-9) saw 2 new severe cases and 1 death. 

    50% of severe cases have not received the seasonal COVID-19 vaccine. 

    This season (October 1, 2026 - September 30, 2027) saw a cumulative total of 77 severe cases, including 14 deaths. 

    The majority of severe cases were among those aged 65 and above (61.0%) and those with a history of chronic illnesses (84.4%). 98.7% of these cases were not vaccinated against COVID-19 this season.

(...)


Source: Centers for Disease Control and Prevention, Taiwan, https://www.cdc.gov.tw/Bulletin/Detail/HHbAdjZ5sQg8nHVyP5QXSQ?typeid=9

____

Friday, November 6, 2026

Weekly #US #Influenza #Surveillance #Report: Key Updates for Week 43, ending October 31, 2026 (CDC, Summary): #H1N1pdm09 vastly predominated



{Extract, Summary}

(...)


Key Points

    ° Multiple seasonal influenza surveillance indicators continue to increase in many parts of the country.

    ° This early-season influenza activity is currently higher than typically observed at this time of year, but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater overall severity.

    ° During Week 43 (the week ending October 31, 2026), of the 513 influenza viruses reported by public health laboratories, 502 were influenza A and 11 were influenza B. Of the 388 influenza A viruses subtyped during Week 43, 379 (97.7%) were influenza A(H1N1)pdm09, 7 (1.8%) were A(H3N2) and 2 (0.5%) were influenza A(H5).

    ° Since Week 21 (the week ending May 30, 2026), 83.4% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been D.3.1.1 HA subclade.

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have caused seasonal epidemics globally since then. Influenza viruses are constantly changing, often requiring updates to influenza vaccine viruses each season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. Recently circulating influenza A(H1N1)pdm09 viruses (which are in an HA subclade called "D.3.1.1") have divided into distinct groups with different genetic changes in their HA genes. We are seeing more genetic diversity among co-circulating A(H1N1)pdm09 viruses than we have before.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season.

    ° Two pediatric deaths associated with season influenza virus infection and occurring during the 2026-27 influenza season were reported to CDC this week.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° The preliminary in-season severity assessment has classified the severity of influenza activity at this point in the season as low across all ages and for children (0-17years), adults (18-64 years) and older adults (65+ years). The severity assessment for the season may change as flu activity is currently increasing.

    ° CDC estimates that there have been at least 1,700,000 illnesses, 25,000 hospitalizations, and 1,400 deaths from flu so far this season.

    ° CDC’s FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits due to flu for the week ending November 21. The number of new flu hospital admissions is forecast to range from 6,900 to 30,100 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1.6% to 6.7%.

    ° Annual seasonal influenza (flu) vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1

    ° Two confirmed cases of avian influenza A(H5) virus infection were reported to CDC this week, including one death. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)


Novel Influenza A Virus Infections

    ° Two confirmed human infections with avian influenza A(H5) virus were reported to CDC this week, including one death. To date, human-to-human transmission of avian influenza A(H5) virus has not been identified in the United States.

    ° Both cases were reported by the Washington State Department of Health and occurred in adults aged ≥18 years who worked at commercial dairy cattle farms where highly pathogenic avian influenza (HPAI) A(H5N1) virus has been detected in cows.

    ° One individual developed respiratory symptoms during the week ending October 24, 2026 (Week 42). The patient presented to an emergency department the following week, was hospitalized, and has died. A respiratory specimen collected at the healthcare facility tested positive for influenza A and was presumptive positive for influenza A(H5) at the University of Washington. The specimen was sent to the Washington State Public Health Laboratory where influenza A(H5) was confirmed using the CDC influenza A(H5) assay. Additional testing conducted by the University of Washington determined this was an avian influenza A(H5N1) virus.

    ° The second individual developed conjunctivitis and sought healthcare. Specimens were collected from the individual and tested at the state public health laboratory using the CDC influenza A(H5) assay during the week ending October 31, 2026 (Week 43). Influenza A(H5) virus was confirmed by the state public health laboratory. The specimen has been shipped to CDC for additional testing.

    ° There has been a total of three influenza A(H5) cases in dairy workers in Washington.

(...)


Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/fluview/surveillance/2026-week-43.html

____

#Influenza virus characteristics, week 40 2025 to week 33 2026, #EU/EEA (ECDC, Nov. 6 '26)


 

{Summary}


Surveillance and monitoring | 6 November 2026


This report summarises influenza virological surveillance data from all 30  European Union and European Economic Area (EU/EEA) countries from week 40  2025 to week 33 2026, as reported by National Reference Laboratories (NRLs) to  The European Surveillance System (TESSy) at the European Centre for Disease  Prevention and Control.


Executive summary

Detections

    Within the reporting period, 256 967 influenza virus detections (sentinel and non-sentinel combined) were reported, of which 249 514 (97.1 %) were type A and 3 292 (1.3 %) were type B viruses; another 4 161 viruses were reported untyped. 

    Of the 56 946 subtyped influenza A viruses (23 % of type A viruses), 20 072 (35 %) were A(H1)pdm09 and 36 874 (65 %) were A(H3). 

    Of the 3 292 reported influenza type B viruses, the lineage for 372 (11 %) was determined as all falling into the B/Victoria/2/87-lineage (B/Victoria).


A(H1N1)pdm09

    For A(H1N1)pdm09 viruses, 25 countries reported 6 636 haemagglutinin (HA) sequences. 

    Of all A(H1N1)pdm09 viruses, the majority belonged to clade 5a.2a.1, newly emerged subclade D.3.1.1 (6 270, 95 %), defined by HA substitutions R113K, A139D, E283K and K302E and which was not represented by any reporting category or reference strain defined for this season. 

    Within the genetic diversification of 5a.2a.1 clade, 340 (5 %) viruses belonged to subclade D.3.1, carrying HA substitutions T216A, T120A, I372V, I460T, V520A and was represented by A/Missouri/11/2025 egg- and cell-based vaccine strains for northern hemisphere 2026-2027 influenza season.

    Among the 838 antigenically characterised A(H1)pdm09 viruses, the main reported categories were A/Missouri/11/2025-like, clade 5a.2a.1(D.3.1) and A/Victoria/4897/2022-like, clade 5a.2a.1(D), representing 44.2 % and 51.1 %, respectively.

    In total, 6 612 A(H1N1)pdm09 viruses were assessed for antiviral susceptibility to oseltamivir and/or zanamivir and/or baloxavir marboxil by 25 countries. 

    Phenotypically assessed reduced and highly reduced inhibition by Oseltamivir was observed for ten (2.3 %) and three (0.7 %) of the 437 tested A(H1N1)pdm09 viruses. 

    Genetic substitutions associated with reduced and highly reduced inhibition by Oseltamivir were observed for 147 (2.4 %, associated with neuraminidase (NA) gene substitutions I223V and S247N mainly, or NA_I223M/T or NA_S247R) and 15 (0.2 %, associated with NA_H275Y or NA_N295S) of the 6 088 assessed viruses, respectively. 

    For Zanamivir, substitutions associated with reduced and highly reduced inhibition were observed for one (<0.1 %, associated with NA_S247R) and one (<0.1%, associated with NA_Q136K) of the 6 089 assessed viruses, respectively. 

    Out of the 4 020 assessed A(H1N1)pdm09 viruses for baloxavir marboxil, substitutions associated with reduced susceptibility were observed for four (0.1 %, associated with polymerase acidic (PA) protein gene substitutions E23G or PA_A37T or PA_E199G/K) viruses.


A(H3N2)

    For A(H3N2) viruses, 25 countries reported 9 538 HA sequences. 

    All A(H3) HA sequences fell into clade 2a.3a.1 and there to seven different subclades. 

    Most viruses (8 808, 92%) fell into newly emerged subclade K (former J.2.4.1) characterised by K2N, S144N (a potential addition of an N-glycosylation site), N158D, I160K, Q173R, T328A and S378N and represented by A/Norway/8765/2025. 

    The remaining 719 A(H3N2) viruses belonged to subclades J.2 (83, 0.9%; which is the NH 2025-26 season vaccine strain represented by A/Croatia/10136RV/2023), J.2.2 (47, 0.5%), J.2.3 (235, 2.5%), J.2.4 (47, 0.5%) and J.2.4.2 (307, 3.2%).

    Among the 1 137 antigenically characterised A(H3) viruses, the main reported categories were A/Croatia/10136RV/2023-like, subclade J.2, A/Singapore/GP20238/2024-like, subclade J.2.4 and A/Norway/8765/2025-like, subclade K, representing 43.3 %, 34.7 % and 10.6 %, respectively.

    In total, 9 441 A(H3N2) viruses were assessed for antiviral susceptibility to oseltamivir and/or zanamivir and/or baloxavir marboxil by 25 countries. 

    Phenotypically assessed reduced inhibition to Oseltamivir was observed for one (0.2%) of the 505 tested A(H3N2), and reduced inhibition to Zanamivir was observed for one (0.2%) of 491 tested A(H3N2) viruses. 

    Genetic substitutions associated with reduced and highly reduced inhibition by Oseltamivir were observed for 19 (0.2%, associated with NA_S331R mainly or NA_K249E or NA_N329R) and three (<0.1%, associated with NA_E119V or NA_del245-248/247-250), respectively, of the 8 869 viruses that could be assessed. 

    Reduced inhibition by Zanamivir was observed for 17 (0.2%, associated with NA_S331R mainly or NA_del245-248/247-250) among the 8 883 viruses that could be assessed. 

    Out of the 5 397 assessed A(H3N2) viruses, substitutions associated with reduced susceptibility for baloxavir marboxil were observed for seven (0.1%, associated with PA_I38L) A(H3N2) viruses.


B/Victoria

    For B/Victoria viruses, 14 countries reported 318 HA sequences. 

    The majority (288, 91%) of the viruses fell in the branch of subclade C.5 defined by D197E, compared with NH 2025-26 vaccine virus B/Austria/1359417/2021_Egg. 

    In that clade, the B/Victoria viruses fell into subclades C.5.6 (126, 40%), C.5.6.1 (89, 28%), C.5.1 (54, 17%) and C.5.7 (18, 6%). 

    Twenty-eight (9%) viruses represented the subclade C.3, where half of them belonged to subclade C.3.1 and half to C.3.3.

    The 21 antigenically characterised B/Victoria viruses were all reported as B/Austria/1359417/2021-like, subclade C.

    None of the 298 genotypically and 14 phenotypically tested B/Victoria viruses showed reduced susceptibility to neuraminidase inhibitors or baloxavir marboxil (when 250 viruses were tested for baloxavir).


Source: European Centre for Disease Control and Prevention, https://www.ecdc.europa.eu/en/publications-data/influenza-virus-characteristics-week-40-2025-week-33-2026-eueea

____

Tuesday, November 3, 2026

#Pathogenicity and #zoonotic potential of a novel pdm09-lineage #H1N2 swine #influenza A virus spatiotemporally linked to transboundary #pig trade

 


Abstract

International swine trade can disseminate influenza A viruses across borders, creating opportunities for reassortment with endemic swine viruses and the emergence of novel strains with zoonotic potential. Here, we characterize a novel H1N2 reassortant, A/swine/Korea/1030–3/2023 (1030–3), detected in South Korea and spatiotemporally associated with European swine lineages and international pig movement. 1030–3 harbors seven gene segments (PB2, PB1, PA, HA, NP, M and NS) closely related to a recent Danish zoonotic H1N1 virus of the 2009 pandemic (pdm09) lineage, and an N2 segment derived from an endemic Korean HxN2. In vitro assays demonstrated that 1030–3 preferentially bound human-type α2,6-linked sialic acid receptors and replicated efficiently in polarized human airway epithelial cells, although these properties were also observed in the endemic Korean H1N2 comparator 1027–1. In mice, 1030–3 caused moderate clinical signs and respiratory replication comparable to an early pdm09 reference strain NL09. In guinea pigs, 1030–3 transmitted to a subset of direct-contact animals but showed no detectable aerosol transmission under the conditions tested. In pigs, the natural host, 1030–3 replicated efficiently and transmitted to all direct-contact animals, with high respiratory shedding and a greater cumulative shedding burden in contact pigs than NL09. Contemporary human sera showed reduced neutralizing activity against 1030–3 relative to both human seasonal H1N1 and 1027–1, while antiserum against a recent H1N1 vaccine antigen also neutralized 1030–3 less efficiently. These findings identify a European-associated H1N2 swine influenza reassortant detected in South Korea that combines a distinct pdm09-derived genomic and antigenic background with efficient replication and transmission in pigs, α2,6-linked receptor preference, and reduced neutralization by human sera, underscoring the need for trade-aware surveillance of swIAVs and continued monitoring at the swine-human interface.


Source: PLoS Pathogens, https://doi.org/10.1371/journal.ppat.1014779

____

#Taiwan, Seasonal #Influenza and #COVID19 Epidemics - Weekly Situation #Report (CDC, Nov. 3 '26): #H1N1pdm09 flu virus & #SARS-CoV-2 PQ.16.1.1 still predominated

 


{Excerpts}

(...)

    The Taiwan Centers for Disease Control (CDC) pointed out that while the domestic influenza epidemic is declining, it is still in its prevalent period. 

    In week 43 (October 25-31), there were 95,916 outpatient and emergency room visits for influenza-like illnesses, a 7.3% decrease from the previous week. 

    Additionally, last week (October 27-November 2), there were 151 new cases of severe influenza complications (146 H1N1, 2 H3N2, 2 unidentified A cases, and 1 B case) and 46 deaths (all H1N1). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 92.7%. 

    This season (October 1, 2026 - September 30, 2027) saw a cumulative total of 542 severe cases (531 H1N1, 2 H3N2, 6 unclassified A cases, and 3 B cases) and 95 deaths (92 H1N1 and 3 unclassified A cases). 

    The majority of severe cases were among those aged 65 and above (69.0%) and those with a history of chronic illnesses (85.4%). 98.3% of those affected had not received the seasonal influenza vaccine.


    According to data from the Taiwan Centers for Disease Control and Prevention (CDC), the COVID-19 epidemic in Taiwan continues to decline. 

    In week 43 (October 25-31), there were 1,834 outpatient and emergency room visits related to COVID-19, a 28.7% decrease compared to the previous week (October 18-24). 

    Last week (October 27-November 2), there were 11 new severe cases and 3 new deaths. 

    This season, there have been a total of 75 severe cases, including 13 deaths. 

    The majority of severe cases are among those aged 65 and above (60.0%) and those with a history of chronic illness (84.0%), none of whom had received the COVID-19 vaccine this season. 

    In the past four weeks, the most common variant strain in locally transmitted cases is PQ.16.1.1, followed by NB.1.8.1.

(...)

Source: Taiwan Centers for Disease Control and Prevention, https://www.cdc.gov.tw/Bulletin/Detail/57M9H7NQtbjNyO5ygCgNiA?typeid=9

____

Friday, October 30, 2026

Weekly #US #Influenza #Surveillance #Report: Key Updates for Week 42, ending October 24, 2026 (CDC, summary)

 


{Summary}

(...)


Key Points

    ° Seasonal influenza activity remains low nationally, but multiple surveillance indicators have been increasing since late August/early September 2026.

    ° This early-season influenza activity is currently higher than typically observed at this time of year but an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater overall severity.

    ° During Week 42 (the week ending October 24, 2026), of the 466 influenza viruses reported by public health laboratories, 456 were influenza A and 10 were influenza B. Of the 371 influenza A viruses subtyped during Week 42, 367 (98.9%) were influenza A(H1N1)pdm09 and 4 (1.1%) were A(H3N2).

    ° Since Week 21 (the week ending May 30, 2026), 82.7% of the influenza A viruses reported have been A(H1N1)pdm09 and among these, the majority have been D.3.1.1 HA subclade.

    ° The influenza A(H1N1) viruses detected this season are still A(H1N1)pdm09 viruses, which emerged in 2009 and have caused seasonal epidemics globally since then. Influenza viruses are constantly changing, often requiring updates to influenza vaccine viruses each season.

    ° Historically, influenza A(H1N1)pdm09 viruses have changed less often than A(H3N2) viruses. Recently circulating influenza A(H1N1)pdm09 viruses (which are in an HA subclade called "D.3.1.1") have divided into distinct groups with different genetic changes in their HA genes. We are seeing more genetic diversity among co-circulating A(H1N1)pdm09 viruses than we have before.

    ° It is too early to know what viruses may predominate or to say whether there might be implications on flu vaccine effectiveness this season.

    ° The first influenza-associated pediatric death occurring during the 2026-27 influenza season was reported to CDC this week.

    ° Because case investigation takes time, flu-associated deaths in children may be reported to CDC weeks after they occur; counts are preliminary and may increase. All reported cases meet the influenza-associated pediatric mortality case definition.

    ° CDC estimates in-season disease burden across all ages each week. CDC estimates that there have been at least 1,000,000 illnesses, 16,000 hospitalizations, and 900 deaths from flu so far this season.

    ° CDC's FluSight forecasts predict a likely increase nationally in both flu hospital admissions and the percentage of emergency department visits associated with flu for the week ending November 14, 2026. The number of new flu hospital admissions is forecast to range from 4,800 to 23,200 admissions, while the national percentage of emergency department visits due to flu is forecast to range from 1% to 4.4%.

    ° Annual seasonal influenza (flu) vaccination is recommended. Influenza vaccines are available for persons aged 6 months and older. People who are recommended for influenza vaccination but have not been vaccinated yet this season are encouraged to be vaccinated now.

    ° There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for influenza complications.1

    ° Influenza viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.

(...)

Source: US CDC, FluView, https://www.cdc.gov/fluview/surveillance/2026-week-42.html

____

Tuesday, October 27, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics - Weekly #Update (CDC, Oct. 27 '26): #H1N1pdm09 flu virus & #SARS-CoV-2 PQ.16.1.1 predominated

 


{Extracts}

(...)

    According to data from the Taiwan Centers for Disease Control (CDC), the domestic influenza epidemic is currently in its peak season. 

    During week 42 (October 18th-24th), there were 101,746 outpatient and emergency room visits for influenza-like illnesses, a decrease of 18.8% compared to the previous week, mainly due to outpatient closures caused by the typhoon holiday. 

    Last week (October 20-26), 85 new cases of severe influenza complications were reported (79 H1N1, 6 unidentified A cases) and 28 deaths (27 H1N1, 1 unidentified A case). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 93.4%. 

    This flu season (2026-2027) has seen a cumulative total of 391 severe cases (380 H1N1, 9 unidentified A cases, 2 type B cases) and 57 deaths (54 H1N1, 3 unidentified A cases). 

    The majority of severe cases are among those aged 65 and above (69.1%) and those with a history of chronic illness (85.2%), and 99.7% of those who did not receive the flu vaccine this season. 

    While the number of COVID-19 cases has continued to decline recently, severe cases and deaths are still occurring. 

    In week 42 (October 18-24), there were 2,534 outpatient and emergency room visits related to COVID-19, a 35.3% decrease compared to the previous week (October 11-17). 

    Last week (October 20-26), there were 8 new severe cases and 4 new deaths. 

    This quarter (October 1, 2026-September 30, 2027) has seen a cumulative total of 64 severe cases, including 10 deaths. 

    In the past four weeks, the most common local variant strain has been PQ.16.1.1, followed by NB.1.8.1.

(...)

Source: 


____

Tuesday, October 20, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics - Weekly #Report (CDC, Oct. 20 '26): #H1N1pdm09 flu virus & #SARS-CoV-2 PQ.16.1.1 variant predominated

 


{Excerpts}

(...)

    According to CDC monitoring data, the domestic influenza epidemic is slowing but still high and in its peak season. 

    During week 41 (October 11-17), there were 123,820 outpatient and emergency room visits for influenza-like illnesses, a 5.4% decrease from the previous week. 

    Last week (October 13-19), 159 new cases of severe influenza were reported (151 H1N1, 7 unidentified A, and 1 B), and 44 deaths were reported (42 H1N1 and 2 unidentified A). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 92.7%. 

    This flu season (2026-2027) has seen a cumulative total of 307 severe cases (298 H1N1, 7 unidentified A, and 2 B) and 42 deaths (40 H1N1 and 2 unidentified A). 

    Furthermore, the domestic COVID-19 epidemic has remained below the epidemic threshold for two consecutive weeks, indicating that the epidemic period has ended. 

    In week 41 (October 11-17), there were 3,873 outpatient and emergency room visits for COVID-19, a 27.7% decrease compared to the previous week (October 4-10). 

    In the past seven days (October 13-19), there were 25 new severe cases and 5 deaths. 

    This season (October 1, 2026-September 30, 2027), there have been a cumulative total of 56 severe cases, including 6 deaths. 

    In the past four weeks, the most common local variant strain has been PQ.16.1.1, followed by NB.1.8.1.

(...)

Source: 


____

Wednesday, October 14, 2026

Mice immunized with #N1 NA in a single cycle infectious virus or in a recombinant nanoparticle #vaccine are protected against lethal challenge with HPAI #H5N1 influenza

 


Abstract

The recent spillover of highly pathogenic (HP) H5N1 clade 2.3.4.4b into dairy cattle and other mammalian species has been concerning. Vaccine candidates that can be rapidly synthesized and implemented are key countermeasures for protecting the human population against emerging pathogens. Here we examine the use of a pH1N1 virus lacking the genetic material for hemagglutinin (HA), limiting the infection to a single cycle (sciIAV) or Cobalt lipid-porphyrin nanoparticles decorated with neuraminidase (NA) of HPAI H5N1 (N1-CoPoP) as vaccine candidates. C57BL/6 mice that were inoculated intranasally with a single dose of pH1N1 sciIAV did not differ in serum NA antibody compared to uninoculated mice. However, mice that were inoculated intramuscularly with the N1-CoPoP alone or in combination with pH1N1 sciIAV had increased N1 IgG antibodies. Upon lethal challenge with HPAIV H5N1, all mice inoculated with either pH1N1 sciIAV or N1-CoPoP were protected from weight loss, unlike unvaccinated mice with substantial body weight losses that succumb to viral infection between 7 and 10 days post infection (dpi). Both pH1N1 sciIAV and N1-CoPoP immunization minimized viral infection such that only one mouse receiving pH1N1 sciIAV had detectable viral titer in the lungs at 4 dpi. By 6 dpi, no mouse inoculated with pH1N1 sciIAV and/or N1-CoPoP had detectable virus in nasal turbinates, lungs or the brain, unlike the high viral titers found in uninoculated mice. Both pH1N1 sciIAV and N1-CoPoP were protective and should be investigated further as alternative vaccine candidates.


Competing Interest Statement

J.F.L. holds interest in POP Biotechnologies. Other authors declare no competing interests.


Funder Information Declared

American Lung Association, https://ror.org/01p3rh655

Texas Biomedical Research Institute

Douglass Foundation

Source: 


Link:  https://doi.org/10.64898/2026.10.11.758125

____

Tuesday, October 13, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics - Weekly Surveillance #Report (CDC, Oct. 13 '26): #H1N1pdm09 flu virus and #SARS-CoV-2 PQ.16.1.1 predominated

 


{Excerpts}

(...)

    According to CDC monitoring data, the domestic influenza epidemic is slowing down but is still in its epidemic period. 

    In week 40 (October 4-10), there were 128,847 outpatient and emergency room visits for influenza-like illnesses, a decrease of 8.9% from the previous week. 

    Last week (October 6-12), there were 144 new cases of severe influenza complications (132 H1N1, 10 untyped A, and 2 B) and 46 deaths (all H1N1). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 91.8%. 

    This influenza season (115-116) saw a total of 149 severe cases (139 H1N1, 9 untyped A, and 1 type B) and 15 deaths (all H1N1). 

    The previous influenza season (114-115) saw a total of 1,887 severe cases (1,259 H1N1, 511 H3N2, 25 untyped A, and 92 type B) and 409 deaths (278 H1N1, 107 H3N2, 12 untyped A, and 12 type B). 

    Among the severe cases, the majority were elderly people over 65 years old (66.3%) and those with a history of chronic diseases (83.6%). 67.1% of the patients had not received the seasonal influenza vaccine. 

    The domestic COVID-19 epidemic is declining. 

    In the 40th week (October 4-10), there were 5,261 outpatient and emergency room visits for COVID-19, a 35.2% decrease compared to the previous week (September 27-October 3). 

    Last week (October 6-12), there were 21 new severe cases and 15 deaths. 

    This quarter (October 1, 2026-September 30, 2027) has seen a cumulative total of 31 severe cases, including 5 deaths. 

    In the previous quarter (October 1, 2025-September 30, 2026), there were a cumulative total of 783 cases of COVID-19 complicated by severe illness, including 173 deaths. 

    The majority of severe cases were among the elderly aged 65 and above (73.7%) and those with a history of chronic diseases (83.0%). 83.8% of them had not received the COVID-19 vaccine this season. 

    In the past four weeks, the most common local variants have been PQ.16.1.1 and NB.1.8.1.

(...)

Source: 


____

Tuesday, October 6, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics - Weekly Situation #Update (CDC, Oct. 6 '26): #H1N1pdm09 flu virus & #SARS-CoV-2 PQ.16.1.1 predominate

 


{Excerpt}

(...)

    According to CDC monitoring data, the domestic influenza epidemic remains stable and is still in its epidemic period. 

    In week 39 (September 27 - October 3), there were 139,060 outpatient and emergency room visits for influenza-like illnesses, a slight decrease of 1.4% from the previous week. 

    Last week (September 29 - October 5), there were 219 new cases of severe influenza complications (210 H1N1, 1 H3N2, 7 unidentified A cases, and 1 B case) and 44 deaths (41 H1N1, 1 H3N2, and 2 unidentified A cases). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 90.7%. 

    This flu season (2025-2026) saw a total of 30 severe cases (all H1N1); the previous flu season (2024-2025) saw a total of 1,862 severe cases (1,225 H1N1, 511 H3N2, 35 unidentified A cases, and 91 B cases) and 378 deaths (247 H1N1, 107 H3N2, 12 unidentified A cases, and 12 B cases). 

    Among the severe cases, the majority were elderly people over 65 years old (66.4%) and those with a history of chronic diseases (83.6%), and 67.2% had not received the flu vaccine for this season. 

    Regarding the COVID-19 pandemic, the number of COVID-19 cases in the country has declined, but it is still in the epidemic period. 

    In the 39th week (September 27 - October 3), there were 7,836 outpatient and emergency visits for COVID-19, a decrease of 26.7% compared with the previous 7 days (September 24 - September 30). 

    Last week (September 29 - October 5), there were 37 new local severe cases and 16 local deaths. 

    This quarter (October 1, 2026 - September 30, 2027) saw a cumulative total of 12 local severe cases, with no deaths. 

    In the previous quarter (October 1, 2025 - September 30, 2026), there were a cumulative total of 781 local cases of COVID-19 complicated with severe illness, of which 163 died. 

    The majority of severe cases were among the elderly aged 65 and above (73.6%) and those with a history of chronic diseases (83.0%). 83.9% of these cases had not received the COVID-19 vaccine that quarter. In the past four weeks, the most common local case variants were PQ.16.1.1 and NB.1.8.1.

(...)

Source: 


____

Saturday, October 3, 2026

Increased circulation of #influenza #H1N1pdm09 viruses with reduced susceptibility to #oseltamivir, #Germany 2024–2026

 


Highlights

    • The National Influenza Center for Germany (Germany NIC) detected an increase in the prevalence of A(H1N1)pdm09 viruses carrying the neuraminidase substitution NA-S247N, rising from 1.16% circulating in the 2024/25 influenza season to 56.8% in the 2025/26 season.

    • The NA-S247N substitution reduced oseltamivir susceptibility slightly; combined NA-S247N/NA-I223V/T substitutions showed reduced inhibition according WHO criteria.

    • Continuous molecular and phenotypic surveillance is essential for public health and the early detection of viruses with reduced susceptibility to antiviral drugs.

    • Rapid pyrosequencing supports the routine surveillance of neuraminidase substitutions associated with reduced susceptibility to antivirals.

    • The findings illustrate the Germany NIC's 30-year contribution to antiviral susceptibility monitoring.



Abstract

Background

Oseltamivir is still considered to be the first-line antiviral treatment for severe seasonal influenza. However, resistance to neuraminidase (NA) inhibitors poses significant challenges to influenza management. Since the 2023/24 season, A(H1N1)pdm09 viruses carrying neuraminidase substitutions (NA-I223V and/or NA-S247N) have emerged in Germany, other EU/EEA countries, and some of the World Health Organization (WHO) regions. These viruses have been linked to reduced oseltamivir susceptibility.

Methods

A rapid RT-PCR/pyrosequencing assay was developed and validated to detect NA-I223X and NA-S247X substitutions. Subsequently, a total of 765 A(H1N1)pdm09 viruses detected in Germany during the 2024/25 and 2025/26 influenza seasons were characterized phenotypically using fluorometric NA inhibition testing and/or genotypically using next-generation sequencing and pyrosequencing.

Results

The prevalence of A(H1N1)pdm09 viruses bearing the NA-S247N substitution increased from 1.2% in the 2024/25 season to 56.8% in the 2025/26 season, accounting for up to 80% of analyzed viruses by March 2026. Viruses carrying NA-S247N exhibited higher oseltamivir IC50 values than wild-type viruses. Combinations of NA-S247N with substitutions at position 223 demonstrated an additional increase. In viruses carrying the combined NA-S247N and NA-I223V/T substitutions oseltamivir showed reduced inhibition with increased IC50 values of up to 17-fold compared to wild type viruses.

Conclusions

The accumulation of NA substitutions in A(H1N1)pdm09 influenza viruses, particularly NA-S247N in combination with NA-I223V/T, substantially reduces susceptibility to oseltamivir. The marked increase in NA-S247N prevalence suggests that this substitution is becoming persistent rather than transient. Targeted pyrosequencing is a practical tool for the early detection of emerging resistance-associated substitutions.

Source: 


Link: https://doi.org/10.1016/j.ijmm.2026.151745

____

Wednesday, September 30, 2026

Substitutions affecting the HA–NA– #receptor #balance preceded the emergence of the #pandemic 2009 #H1N1 virus

 


Abstract

Swine are a crucial species in influenza A virus (IAV) ecology, capable of supporting replication and consequently evolution of human, avian, and swine strains. They are also the source of the 2009 pandemic H1N1 virus (H1N1pdm09). Understanding how swine IAV breach the species barrier is essential for detection of potentially pandemic viruses, but is often overlooked compared to avian IAV. We hypothesize that the HA–NA balance of (pre)pandemic swine viruses is a key feature that needs adjustment as swine and humans differ in their sialoglycome. We focused on a set of (pre)pandemic swine viruses collected in Mexico following the H1N1pdm09 emergence. Phylogenetic analysis showed that the emergence was preceded by substitutions in HA and NA predicted to affect their function. Thus, HA acquired substitution A227E, previously shown to reduce receptor binding in H1N1pdm09, while NA obtained substitution S369N in the 2nd sialic acid binding site (2SBS) predicted to reduce NA cleavage. The substitutions’ effect on the HA–NA balance, was confirmed with biolayer interferometry using recombinant proteins attached to nanoparticles. Engineering recombinant attenuated influenza viruses with swine HA and NA with/without the mentioned substitutions, showed that the 2SBS substitution negatively affected replication in primary human and swine cultures. Interestingly, replication was restored by the HA substitution. Overall, we show that the emergence of H1N1pdm09 in humans was preceded by substitutions in HA and NA that were acquired in swine and adjusted the HA–NA balance. We hypothesize that adjustment of the HA–NA balance was a critical step for crossing the host–species barrier.

Source: 


Link: https://doi.org/10.1073/pnas.2609870123

____

Tuesday, September 29, 2026

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics Weekly #Report (CDC, Sept. 29 '26): #H1N1pdm09 flu virus and #SARS-CoV-2 PQ.16.1.1 variant predominated

 


{Excerpts}

(...)

    According to data from the Taiwan Centers for Disease Control (CDC), the influenza epidemic in Taiwan remains stable and is still in its prevalent period. 

    In week 38 (September 20-26), there were 138,654 outpatient and emergency room visits for influenza-like illnesses, a slight decrease of 3.2% compared to the previous week, mainly due to outpatient closures during the long weekend. 

    Additionally, last week (September 22-28), there were 87 new severe cases of influenza (80 H1N1, 1 H3N2, and 6 untyped A cases) and 30 deaths (all H1N1). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 87.7%. 

    This flu season (2015-2016) saw a cumulative total of 1,673 severe cases (1,041 H1N1, 510 H3N2, 32 unclassified H1N1, and 90 H1N1) and 334 deaths (206 H1N1, 106 H3N2, 10 unclassified H1N1, and 12 H1N1). 

    The majority of severe cases were among those aged 65 and above (65.9%) and those with a history of chronic illnesses (83.4%). 67.7% of patients had not received the flu vaccine this season. 

    Regarding the COVID-19 pandemic, while the number of cases in Taiwan has decreased, it remains in an epidemic period. 

    In week 38 (September 20-26), there were 10,502 outpatient and emergency room visits related to COVID-19, a 28.4% decrease compared to the previous week (September 13-19). 

    Last week (September 22-28), there were 33 new severe cases and 14 new deaths. 

    Since October 2025, there have been a total of 756 cases of COVID-19 complicated by severe illness, of which 147 have died. 

    The majority of severe cases are among the elderly aged 65 and above (73.7%) and those with a history of chronic diseases (82.9%). 83.6% of these cases have not received the COVID-19 vaccine this season. 

    In the past four weeks, the most prevalent local case variants have been PQ.16.1.1 and NB.1.8.1.

(...)

Source: 


____

My New Space

Most Popular Posts